Scientific Article

Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking

Avinash R. Chaurasia MD a,*, Kelly J. Sun MS b, Christopher Premo MD c, Timothy Brand MD c, Brent Tinnel MD c, Stacie Barczak RN d, John Halligan MD e, Michael Brown MD f, Dusten Macdonald MD d

a National Cancer Institute, National Institutes of Health, National Capitol Consortium Residency Program, Bethesda, Maryland
b Uniformed Services University of Health Sciences, Bethesda, Maryland
c Madigan Army Medical Center, Tacoma, Washington
d Geneva Foundation, Tacoma, Washington
e Providence Alaska Medical Center, Anchorage, Alaska
f Central Maine Radiation Oncology, Lewiston, Maine

Received 16 February 2018; revised 12 June 2018; accepted 28 June 2018

Abstract

Purpose: The aim of this study is to quantify and describe the feasibility, clinical outcomes, and patient-reported outcomes of reduced planning target volume (PTV) margins for prostate cancer treatment using real-time, continuous, intrafraction monitoring with implanted radiation frequency transponder beacons.

Methods and materials: For this prospective, nonrandomized trial, the Calypso localization system was used for intrafraction target localization in 31 patients with a PTV margin reduced to 2 mm in all directions. A total of 1333 fractions were analyzed with respect to movement of the prostate, pauses and interruptions, and dosimetric data. Pre- and posttreatment quality-of-life scores were tracked at baseline, during treatment, and up to 24 months after treatment.

Results: The mean time of daily treatment was 10 minutes, with 96.1% of all treatments falling within a 20-minute treatment window standard. On average, beacon motion exceeded 3 mm during active treatment only 1.76% of the time. The average length of treatment interruption was 34.2 seconds, with an average of 1 interruption every 3.39 fractions. The displacement or excursion of the prostate was the greatest in the superior or inferior dimension (0.11 mm and 0.09 mm, respectively) and anterior or posterior dimension (0.07 mm and 0.13 mm, respectively), followed...
by the left or right dimension (0.05 mm and 0.06 mm, respectively). At 6 months, patients demonstrated a smaller change in Expanded Prostate Cancer Index Composite scores than the ProtecT comparator group (decreased short-term morbidity). However, in the Bowel and Urinary domains at 12 and 24 months, there was no significant difference.

Conclusions: Our data confirm and support that the use of Calypso tracking with intensity modulated radiation therapy reliably provides minimal disruption to daily treatments and overall time of treatment, with the PTV only moving outside of a 3-mm margin < 2% of the time. The use of a 3-mm PTV margin provides adequate dosimetric coverage while minimizing genitourinary and gastrointestinal toxicity.

© 2018 Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Radiation therapy is an effective treatment option for many men with localized prostate cancer. The use of advanced radiation techniques including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) have been shown to reduce gastrointestinal (GI) and genitourinary (GU) toxicities, even in the setting of dose escalation. The addition of daily image guided radiation therapy (IGRT) has led to a further reduction in the dose adjacent to organs at risk and improved toxicity rates by reducing planning target volume (PTV) margins. Several systems have been devised to more precisely localize the target compared with skin markings, including daily ultrasound localization, cone beam computed tomography (CBCT), and implanted fiducial markers or gold seeds with daily orthogonal pretreatment portal imaging. The implementation of these methods have allowed for a reduction in PTV expansion to 5 to 7 mm.

In the past decade, there has been increasing research into intrafraction motion of the prostate related to changes in treatment planning, dosimetry, and radiation-associated toxicities. However, PTV margins still vary widely depending on immobilization and IGRT technique. Recent protocols have mandated PTV margins of 5 to 10 mm, and only in the setting of extremely hypofractionated radiation therapy (SBRT) have margins of <5 mm been considered acceptable in most practices. Many institutions are now using a 5-mm posterior expansion in the setting of IGRT with conventional fractionation. Real-time electromagnetic tracking of the prostate allows for the real-time tracking of internal organ and patient movement, which can allow for a further decrease in PTV margin. In theory, this would lead to a reduction in doses to adjacent organs at risk and reduction in late toxicities.

The current study is a prospective trial using the Calypso four-dimensional localization system to treat patient volunteers with prostate cancer with a clinical target volume to PTV margin of only 3 mm. We evaluated the feasibility, clinical outcomes, and patient-reported quality-of-life outcomes of reduced PTV margins for prostate cancer treatments using real-time continuous intrafraction monitoring with implanted radiation frequency transponder beacons.

Methods and materials

Patient Population

Men with low or intermediate risk of prostate cancer per the National Comprehensive Cancer Network risk groups were treated with definitive IMRT using reduced PTV margins in a prospective, single-institution, non-randomized trial. The eligibility criteria included age > 40 years, histologically confirmed prostate adenocarcinoma, cT1a-cT2c, Gleason score ≤7, prostate-specific antigen ≤15, and Zubrod performance score of 0 or 1. Patients with high risk (per the National Comprehensive Cancer Network), node-positive, or metastatic disease were excluded as well as patients with a history of connective tissue or inflammatory bowel disease, active implanted devices, or prior prostate cancer treatments other than androgen deprivation therapy (ADT). Patients with maximum anterior—posterior separation through the torso minus the height of the center of the prostate > 17 cm were excluded as well for technical reasons. We obtained approval from our institutional review board and ethics committee. Patients provided consent prior to enrollment in this trial.

Treatment planning and margins

Three Calypso Beacon Transponders were implanted in the prostate via rectal ultrasound guidance per the manufacturer’s instructions 4 to 7 days prior to computed tomography simulation. Computed tomography simulation was performed with a full bladder and empty rectum (and daily treatment), with coaching on behavioral and dietary modifications to achieve these goals. Lower extremity Vac-Lok bags were used for immobilization. The normal tissues were contoured per the Radiation Therapy Oncology Group
guidelines. The gross tumor volume was defined as the entire prostate. The apex was defined by either prostate magnetic resonance imaging or urethrogram. For men with low-risk prostate cancer, the clinical target volume (CTV) equaled the gross tumor volume without expansion. For men with intermediate-risk prostate cancer, the CTV equaled the prostate, proximal 1 cm of the seminal vesicles, plus a 3-mm expansion of the prostate (minus rectum and bladder) to account for possible extraprostatic extension. The PTV for all patients was a 3-mm uniform expansion from the CTV. CBCT was typically used once weekly to confirm bladder filling and empty rectum. The prescription dose was 77.4 Gy in 1.8 Gy fractions. The coverage goals included V77.4 Gy/C21 100% of the CTV and V77.4 Gy/C21 98% of the PTV. The maximum dose allowed to the bladder and rectum was 105% (81 Gy). Other constraints for the rectum included 

\[ V_{78\,\text{Gy}} \leq 5\% \quad \text{and} \quad V_{78\,\text{Gy}} < 10\,\text{cm}^3, \]

\[ V_{75\,\text{Gy}} \leq 15\%, \quad V_{70\,\text{Gy}} \leq 25\%, \quad V_{65\,\text{Gy}} \leq 35\%, \quad \text{and} \quad V_{50\,\text{Gy}} \leq 60\%. \]

Other constraints for the bladder included 

\[ V_{80\,\text{Gy}} \leq 15\%, \quad V_{75\,\text{Gy}} \leq 25\%, \quad V_{70\,\text{Gy}} \leq 35\%, \quad \text{and} \quad V_{65\,\text{Gy}} \leq 50\%. \]

All patients received static field IMRT, typically with 7 fields and occasionally up to 9. VMAT was not used because our clinic had not fully implemented VMAT at the time of the beginning of the trial.

### Target localization and tracking

Treatments were delivered using the Calypso Beacons for localization and continuous, real-time tracking with the Calypso system. A 2-mm tracking threshold was utilized such that, if the beacons moved more than 2 mm from their planned position, the therapists intervened to pause the beam until either the beacons returned to an acceptable range on their own or the patient was realigned. In general, a deviation that persisted for >10 seconds would prompt repositioning.

### Table 1  Patient characteristics

| Study                     | ProtecT study | AIM study | PROST-QA cohort |
|---------------------------|---------------|-----------|------------------|
| Number enrolled           | 31            | 545       | 64               |
| Age (y)                   |               |           |                  |
| Median                    | 69            | 69        | 69               |
| Range                     | 50-82         | 55-86     | 47-83            |
| Age group, n (%)          |               |           |                  |
| <60                       | 3 (10)        | 3 (5)     | 22 (14)          |
| 60-69                     | 14 (45)       | 35 (55)   | 66 (43)          |
| >70                       | 14 (45)       | 26 (41)   | 65 (42)          |
| PSA (ng/mL)               |               |           |                  |
| Mean                      | 5.8 (±2.6)    | 8.3 (±6.2)| 6.8 (±4.3)       |
| Median                    | 5.79          | 6.7       | 5.8              |
| Range                     | 1.5-11.3      | 0.6-36.8  | 0.5-25.8         |
| Group, n (%)              |               |           |                  |
| <4 ng/mL                  | 7 (23)        | 9 (14)    | 31 (20)          |
| 4-10 ng/mL                | 22 (71)       | 41 (64)   | 96 (63)          |
| >10 ng/mL                 | 2 (6)         | 14 (22)   | 26 (17)          |
| ADT                       |               |           |                  |
| Yes                       | 0             | 21        | 0                |
| No                        | 31            | 43        | 153              |
| Gleason score on biopsy, n (%) |           |           |                  |
| <7                        | 12 (39)       | 423 (78)  | 32 (5)           |
| 7                         | 19 (61)       | 108 (20)  | 26 (41)          |
| >7                        | 0 (0)         | 14 (3)    | 6 (9)            |
| Clinical stage, n (%)     |               |           |                  |
| T1                        | 20 (65)       | 429 (79)  | 32 (50)          |
| T2                        | 11 (35)       | 116 (21)  | 31 (48)          |
| T3                        | 0 (0)         | 0 (0)     | 1 (2)            |
| Overall cancer risk       |               |           |                  |
| Low                       | 12 (39)       | 15 (23)   | 61 (40)          |
| Intermediate              | 19 (61)       | 41 (64)   | 88 (58)          |
| High                      | 0 (0)         | 8 (13)    | 4 (3)            |
| Other characteristics     |               |           |                  |
| Mean BMI (±SD)            | 27.2 (3.9)    | 28.1 (4.6)| 28.5 (5.4)       |
| Mean prostate volume, mL (±SD) | 45.3 (15.9)  | 61.0 (25.9)| 50.0 (27.0)       |

ADT, androgen deprivation therapy; BMI, body mass index; PSA, prostate-specific antigen; SD, standard deviation.
Patient-reported outcomes

Patients completed the full Expanded Prostate Cancer Index Composite (EPIC) questionnaire prior to radiation therapy, at Week 5 of radiation therapy, at the last fraction of radiation therapy, and at 3, 6, 12, 18, and 24 months after the start of radiation therapy. Three key domains were assessed: Bowel, urinary, and sexual function. We compared morbidity to ProtecT, a contemporary, well-studied cohort of patients who underwent prostate external beam radiation therapy (EBRT; 3-dimensional conformal radiation therapy) using conventional PTV margins. Differences between baseline scores and follow-up EPIC scores were compared between the Calypso and ProtecT patients. Per previous analyses of EPIC scores in prostate cancer radiation therapy, a clinically relevant change in quality of life was defined as a difference from baseline to follow-up that was greater than half a standard deviation of the baseline value.

Results

A total of 31 patients were enrolled in our single-institution study between May 2009 and June 2015. Patient characteristics can be found in Table 1. A total of 1333 fractions (or treatments) were recorded during this time. The follow-up time of patients ranged between 12 and 60 months with formal follow-up as part of the study at 15 months, with a mean follow-up time of 22.45 months.

The mean time of daily treatment was 10 minutes with a standard deviation of 4.80 minutes (minimum: 4 minutes; maximum: 71 minutes). Of all treatments, 96.1% fell within the standard of a 20-minute treatment window. On average, the PTV only spent 1.76% ± 1.69% of beam-on time outside of the 2-mm treatment window.

The average length of a treatment interruption was 34.2 seconds, with an average number of interruptions of 0.30 interruptions per fraction, which is equivalent to an interruption every 3.39 fractions. Each interruption was either a pause, during which the prostate returned to within 2 mm of its planned position on its own, or a reposition that required a couch position intervention by the radiation therapist. The average length of a pause was 17.6 seconds, and the median length was 6 seconds. The average reposition time was 40.5 seconds with a median of 28.5 seconds. Given the disparity between the mean and median for both pauses and repositions, the data is likely skewed by outliers and the median values are more indicative of common pause and reposition times. These data are summarized in Table 2.

The greatest variation in displacement or excursion of the prostate in 3 dimensions was in the superior or inferior dimension (maximum excursion of the prostate during beam-on: 1.1 ± 0.9 mm or 0.9 ± 0.9 mm, respectively) and anterior or posterior dimension (0.7 ± 1.1 mm or 1.3 ± 0.7 mm, respectively). Left or right movement was found to a lesser degree (0.5 ± 0.6 mm or 0.6 ± 0.6 mm, respectively). These data are summarized in Table 3 and Figure 1.

All 31 patients were able to achieve a standard of 98% PTV coverage at 77.4 Gy, with a mean of 98.4% ± 0.5%. The mean rectal volumes at V78 Gy, V75 Gy, and V70 Gy were 2.7% ± 1.6%, 8.2% ± 3.2%, and 14.2% ± 5.3%, respectively. The mean bladder volumes at V80 Gy, V75 Gy, and V70 Gy were 1.0% ± 1.7%, 7.5% ± 4.2%, and 10.8% ± 6.2%, respectively. These data are summarized in Table 4.

The EPIC questionnaire response rate during the follow-up was 95%. Three volunteers stopped completing the questionnaires after 6 to 18 months of follow-up and others did not fully complete every questionnaire. For each domain at baseline, our cohort had similar or slightly lower scores than the comparator group, which indicates a higher prevalence of baseline symptoms that impair quality of life. At 6 months, patients demonstrated a smaller change in scores (ie, better health-related quality of life) than the comparator group in the bowel, urinary, and sexual domains, but this change was only statistically significant in the urinary and sexual domains (P = .14; P = .03; and P < .01, respectively). However, in the bowel and urinary domains at 12 and 24 months, the EPIC scores of patients in the ProtecT trial returned closer to baseline levels, whereas patient scores continued to decrease or remain stable such that there was no significant difference in the EPIC scores of the 2 groups in these domains. In addition, in the sexual domain, patients showed significantly smaller follow-up change in scores at all points of follow-up, but this comparison is confounded by the use of 6 months of ADT in the ProtecT trial.

In the ProtecT cohort at 6 months, a clinically meaningful decline is demonstrated in all 3 domains compared with a clinically meaningful decline only in the bowel scores in the patient group at that time point. At subsequent time points, patients in the ProtecT trial did not demonstrate a clinically meaningful decline in urinary symptoms. Table 5 and Figure 2 summarize the patient reported EPIC scores and changes from baseline for patients and the radiation therapy arm of the ProtecT trial.

### Table 2: Interruption length and breakdown

|                   | Interruption Time (s) | Pause Time (s) | Reposition Time (s) |
|-------------------|-----------------------|----------------|---------------------|
| Mean              | 34.2                  | 17.55          | 40.51               |
| SD                | 33.79                 | 37.56          | 51.21               |
| Median            | 19.68                 | 6              | 28.5                |
| Minimum           | 1                     | 1              | 2                   |
| Maximum           | 601                   | 301            | 501                 |

SD, standard deviation.
Discussion

In the recent ProtecT trial, EBRT had little effect on urinary continence, a stable long-term effect on sexual function, and a worsening effect on bowel function (with recovery) when compared with prostatectomy. Of note, all men in the radiation arm of this trial also received ADT. In addition, the radiation technique was 3-dimensional conformation radiation therapy. To improve EBRT’s toxicity profile, many efforts have been made to improve radiation delivery techniques, including inter- and intrafraction monitoring, to decrease dose delivery to organs at risk.

A common concern about smaller PTV margins is intrafraction motion. There is significant time between obtaining on-board kV imaging and the completion of the daily radiation fraction with multiple field IMRT plans, which leaves more time for intrafraction motion. Using the same technology, Shelton et al. in their study of 37 patients demonstrated that treatment time was the strongest predictor of observed displacements, and that VMAT was associated with reduced motion. Langen et al. reported similar findings that the likelihood of prostate gland movement increased with time, and emphasized the importance of initiating treatment quickly after initially imaging the patient and minimizing overall time of treatment to decrease the likelihood of prostate drift. In a comparison of VMAT with electromagnetic tracking to IMRT with and without electromagnetic tracking, Hall et al. found that VMAT was associated with a decreased time of delivery per treatment. In addition, the researchers found that using VMAT with electromagnetic tracking did not cause a significantly different treatment time compared with previous methods overall. Hall et al. had an average treatment time of 13.81 minutes with VMAT with Calypso tracking.

Our data show a lesser mean treatment time of 10.0±4.80 minutes using the same technologies with IMRT. We suspect that by using VMAT, treatment times would be even shorter. In addition, our data show encouraging reproducibility, with 96.1% of all treatments falling within a standard treatment time of 20 minutes.

Our data confirm and support that using Calypso tracking is time efficient and reproducible.

Our study is one of the first to demonstrate minimal disruption to daily treatments using this new technology. Langen et al. had only 17 of 550 fractions (3.1%) with interventions; however, their protocol did not dictate any interventions on the basis of observed prostate displacement. In a similar study for patients undergoing prostate SBRT with Calypso tracking, Lovelock et al. demonstrated an average of 1.74 interventions or fraction required, with an increase in time of dose delivery of approximately 65 seconds. Even with strict margins <2 mm to require an intervention, we only required 1 intervention every 3.39 fractions, with a mean added time of 34.2 seconds per intervention. Each pause (ie, self-return of the prostate to within 2 mm) was a median of 6 seconds long, and each reposition was a median of 28.5 seconds in duration. Pauses do not appear to contribute significantly

**Table 3** Maximum prostate excursion or displacement during beam-on

| Displacement (mm) | Left | Right | Superior | Inferior | Anterior | Posterior |
|-------------------|------|-------|----------|----------|----------|-----------|
| Mean              | 0.5  | 0.6   | 1.1      | 0.9      | 0.7      | 1.3       |
| SD                | 0.6  | 0.6   | 0.9      | 0.9      | 1.1      | 0.7       |
| Median            | 0.5  | 0.6   | 1.0      | 0.9      | 0.4      | 1.3       |
| Minimum           | −1.1 | −1.2  | −1.4     | −1.2     | −4.0     | −1.1      |
| Maximum           | 6.7  | 6.0   | 10.7     | 11.5     | 11.4     | 4.5       |

SD, standard deviation.

**Figure 1** Patient Mean Prostate Excursion/Displacement During Beam-On.
to treatment time, but repositions tend to be slightly longer.

In addition, we noted that in a few rare instances, repositions required anywhere from to 5 to 8 minutes and were likely due to rectal gas, which may have distorted the prostate and required a CBCT and repositioning. However, given the relatively low rate of interventions (1 intervention every 3.39 fractions) and the relatively small amount of time added on average by either an intervention or pause, our data show that Calypso tracking reliably provides minimal disruption to daily treatments and overall time of treatment. Implementing the Calypso tracking worked seamlessly in our clinic workflow and did not negatively impact patient care.

Many previous studies have tracked prostate intrafraction motion and its displacement or excursion has been well described in the literature.8,13-17,20,23 Mayyas et al. used Calypso tracking and found standard deviations for intrafraction prostate motion of 1.3, 1.5, and 0.6 mm (2 standard deviation values would be 2.6, 3.0, and 1.2 mm) in the anterior or posterior, superior or inferior, and left or right directions, respectively, in a study of 27 patients.15

Shelton et al. also found that shifts were greater in the anterior or posterior and superior or inferior dimensions and were likely related to organ motion, and left or right motion was less and likely related to patient motion.23 Langen et al. described that the prostate’s displacement in all directions was >3 mm for 13.6% of the time, and >5 mm for 3.3% of the time on average.13 Lin et al. looked at respiratory-induced prostate motion and found an oscillatory pattern of the prostate in the anterior or posterior and superior or inferior directions, with 99% of patients showing an average respiratory-induced motion between 0.2 and 2.0 mm.19

In our study, we found prostate motion to be similar to slightly lower than what has generally been described

### Table 4 Dosimetric data

| PTV       | Rectum V77.4 (≥98%) | V78 (≤5%) | V75 (≤15%) | V70 (≤25%) | Bladder V80 (≤15%) | V75 (≤25%) | V70 (≤35%) |
|-----------|---------------------|-----------|------------|------------|-------------------|------------|------------|
| Mean      | 98.4%               | 2.7%      | 8.2%       | 14.2%      | 1.0%              | 7.5%       | 10.8%      |
| SD        | 0.5%                | 1.6%      | 3.2%       | 5.3%       | 1.7%              | 4.2%       | 6.2%       |
| Minimum   | 98.0%               | 0.0%      | 1.3%       | 3.5%       | 0.0%              | 2.5%       | 3.7%       |
| Maximum   | 99.9%               | 6.4%      | 14.9%      | 23.0%      | 7.8%              | 16.6%      | 27.0%      |

PTV, planning target volume; SD, standard deviation; Vx, coverage goal of x Gy.

### Table 5 Patient-reported morbidity comparison (EPIC Scoresa)

| Domain | Our Study (n = 31) | | | | ProtecT (n = 545) | | | |
|--------|-------------------|---------|---------|---------|-------------------|---------|---------|
|        | Score, mean (SD)  | Mean differenceb (95% CI) | Clinically meaningful declinec | Score, mean (SD)  | Mean differenceb (95% CI) | Clinically meaningful declinec | P-value |
| Bowel  |                   |         |         |         |                   |         |         |
| Baseline | 94.1 (6.6)       | -       | -       | -       | 94.8 (6.9)        | -       | -       |
| 6 mo     | 90.5 (12.2)      | -3.6 (-8.5 to 1.3) | Yes | 86.3 (16.0) | -8.5 (-10.4 to -6.6) | Yes | .14 |
| 12 mo    | 87.8 (14.2)      | -6.3 (-11.8 to -0.8) | Yes | 90.5 (12.2) | -4.3 (-5.8 to -2.8) | Yes | .47 |
| 24 mo    | 88.1 (13.7)      | -6.0 (-11.4 to -0.6) | Yes | 89.3 (12.8) | -5.5 (-7.0 to -4.0) | Yes | .86 |
| Urinary |                   |         |         |         |                   |         |         |
| Baseline | 88.9 (10.6)      | -       | -       | -       | 93.2 (8.3)        | -       | -       |
| 6 mo     | 87.2 (13.3)      | -1.7 (-7.7 to 4.3) | No  | 84.7 (13.8) | -8.5 (-10.3 to -6.7) | Yes | .03 |
| 12 mo    | 85.2 (14.4)      | -3.7 (-10.0 to 2.6) | No  | 91.9 (9.0) | -1.3 (-2.7 to 0.1) | No  | .36 |
| 24 mo    | 84.3 (14.4)      | -4.6 (-10.9 to 1.7) | No  | 91.4 (9.8) | -1.8 (-3.2 to -0.4) | No  | .31 |
| Sexual  |                   |         |         |         |                   |         |         |
| Baseline | 48.9 (31.8)      | -       | -       | -       | 63.6 (23.1)       | -       | -       |
| 6 mo     | 41.1 (30.1)      | -7.8 (-23.2 to 7.6) | No  | 31.9 (27.1) | -31.7 (-35.8 to -27.6) | Yes | <.01 |
| 12 mo    | 36.7 (26.2)      | -12.2 (-26.7 to 2.3) | No  | 43.2 (27.6) | -20.4 (-24.5 to -16.3) | Yes | <.01 |
| 24 mo    | 41.7 (29.2)      | -7.2 (-22.4 to 8.0) | No  | 43.4 (25.9) | -20.2 (-24.1 to -16.3) | Yes | <.01 |

CI, confidence interval; EPIC, Expanded Prostate Cancer Index Composite; SD, standard deviation.

a Scores range from 0 to 100, and higher scores indicate better patient-reported quality of life.

b Change from baseline to follow-up, calculated from within-patient differences.

c Mean difference >0.5 SD from baseline value.
previously in the literature. This is in line with research by Bell et al. in a smaller study of only 3 patients, with findings of mean intrafraction motion of \( \leq 0.2 \) cm in all directions.\(^8\) Additionally, the prostate spent only 1.76% of the time outside of our planned tracking constraint of 2 mm. These are strong indicators that 3 mm margins are feasible and safe.

We would expect that a decrease in PTV margin would lead to a decrease in normal tissue toxicity. Michalski et al. showed that IMRT was associated with a reduction in acute GI and GU toxicity, and that keeping \( V_{70\, Gy} \) and \( V_{75\, Gy} \) at <15% and <10%, respectively, was associated with lower rates of GI toxicity.\(^2\) Our \( V_{70\, Gy} \) of 14.2% and \( V_{75\, Gy} \) of 8.2% fell within these margins and would thus be associated with a reduction in toxicities as described by Michalski et al.\(^2\) Zelefsky et al. found that, with inter-fraction monitoring using fiducial markers versus a similar non-IGRT cohort, there was significant reduction in late urinary toxicity.\(^7\) Although previous studies have focused on rectal toxicity, our bladder dosimetry data at \( V_{80\, Gy} \), \( V_{75\, Gy} \), and \( V_{70\, Gy} \) show values that are in line with modern dosimetry standards to decrease GU toxicity.\(^2\)

Patient-reported, health-related outcomes measured by EPIC questionnaire were generally improved or similar when compared with those of the ProtecT radiation therapy arm. Most notably, at 6 months of follow-up, the urinary domain was significantly improved in our study, and changes in sexual function scores remained significantly better compared with those of ProtecT. Although the initial decrements were smaller in our study, the ProtecT radiation therapy cohort showed a trend to return closer to baseline while our study showed stability/small decrements in bowel and urinary scores throughout 24 months of follow-up.

Modeling studies have previously estimated that 3-mm PTV margins in prostate cancer can decrease rectal toxicities by reducing volume of acute normal tissue damage, which can predict late tissue damage.\(^27,28\) This may suggest that the decreased short-term morbidity observed in our study may translate into long-term improvements in morbidity that we were unable to observe in our smaller patient group.

Some observed differences in EPIC scores between our patients and those in the ProtecT trial may be related to differences in technique, lower doses used in the ProtecT trial (74 Gy in 37 fractions), and the fact that all men in the radiation arm of the ProtecT trial were treated with short-term ADT. An ADT-related reduction in prostate size could lead to improved EPIC scores.

Our analysis of patient-reported, health-related outcomes compared with those of the ProtecT radiation therapy arm is consistent with previous analyses of our cohort to the AIM and Prost-QA studies,\(^26,31\) where pre- and post-treatment EPIC-26 survey scores for bowel, urinary irritation/incontinence, and sexual function were compared.\(^32\) A clinically meaningful decline was demonstrated in 2 domains in our study, 1 domain in the AIM study, and 3 domains in the Prost-QA cohort study (Table 6). Furthermore, mean decrements between pre- and posttreatment scores were significantly lower in the AIM study compared with those in our cohort in the urinary irritation domain (\( P = .0009 \)). Our cohort’s results were most similar to those of Prost-QA patients, but worse than the AIM non-neoadjuvant hormonal therapy study cohort in the urinary irritation domain.

Upcoming areas of interest include hypofractionation of localized prostate cancer treatment because prospective trials, such as the Conventional versus Hypofractionated High-Dose Intensity Modulated Radiotherapy for Prostate Cancer trial, have shown noninferiority of hypofractionated treatment and the possibility to decrease...
Advances in Radiation Oncology: October–December 2018 Reduced prostate PTV margins with real-time tracking 637

Scores range from 0-100, and higher scores indicate better patient reported quality of life.

Mean difference

Calypso tracking with reduced PTV margins may serve as an important tool to improve accuracy and minimize toxicity. Further areas of study include the study of intrafraction monitoring in the setting of hypofractionated treatments and prostate SBRT. Concern remains about late toxicities in these treatment regimens, but one way to help reduce this may be with smaller PTV margins and tighter rectal or bladder constraints.

The limitations of our study include the relative small size of the patient population and the fact that the study was performed at a single institution. Future studies that incorporate larger patient populations and more treatment centers may point toward more generalizable ways of incorporating Calypso tracking into routine dosimetric planning and daily treatments.

Conclusions

Our data confirm and support that using Calypso tracking is reliable to provide minimal disruption to daily treatments and overall time of treatment, with the PTV only moving outside of a 3-mm margin <2% of the time. IMRT with Calypso tracking presents an effective way to track the prostate in real time. Using 3-mm PTV margins provides adequate dosimetric coverage while also minimizing GU and GI toxicity. Our decreased, observed, short-term morbidity may translate into long-term improvements in morbidity that we were unable to observe in our smaller patient group. Hypofractionation and prostate SBRT are ongoing areas of research for which Calypso tracking with reduced PTV margins may serve as an important tool to improve accuracy and minimize toxicity.

Table 6 Patient-reported morbidity comparison between studies (EPIC Scores)

| EPIC domain/study (n) | Pretreatment mean (SD) | Post-treatment mean (SD) | Mean difference (95% CI) | Clinically meaningful decline<sup>b</sup> |
|-----------------------|------------------------|--------------------------|--------------------------|-----------------------------------------|
| **Bowel/rectal**      |                        |                          |                          |                                         |
| This study (31)       | 94.1 (18.1)            | 83.81 (15.4)             | −10.5 (−11.5 to −9.5)    | Yes                                     |
| AIM non-NHT study (41)| 91.8 (19.2)            | 89.8 (17.6)              | −1.9 (−9.0 to 5.1)       | No                                      |
| Prost-QA cohort (148) | 94.4 (10.8)            | 78.5 (20.9)              | −16.0 (−19.4 to −12.5)   | Yes                                     |
| **Urinary irritation**|                        |                          |                          |                                         |
| This study (31)       | 88.8 (18.8)            | 70.6 (20.5)              | −18.2 (−19.3 to −17.1)   | Yes                                     |
| AIM non-NHT study (38)| 84.5 (18.0)            | 80.6 (23.0)              | −4.0 (−10.0 to 2.1)      | No                                      |
| Prost-QA cohort (148) | 86.6 (14.3)            | 70.1 (20.7)              | −16.5 (−19.8 to −13.3)   | Yes                                     |
| **Urinary incontinence**|                       |                          |                          |                                         |
| This study (31)       | 90.8 (20.3)            | 86.8 (20.1)              | −4.2 (−5.0 to −3.4)      | No                                      |
| AIM non-NHT study (43)| 93.0 (12.5)            | 86.3 (21.0)              | −6.7 (−12.1 to −1.3)     | Yes                                     |
| Prost-QA cohort (138) | 92.5 (13.1)            | 84.6 (20.5)              | −7.9 (−11.0 to −4.8)     | Yes                                     |
| **Sexual**            |                        |                          |                          |                                         |
| This study (31)       | 48.9 (32.5)            | 41.0 (31.8)              | −7.7 (−9.1 to −6.3)      | No                                      |
| AIM non-NHT study (43)| 50.9 (32.1)            | 50.9 (26.9)              | 0.0 (−8.6 to 8.6)        | No                                      |
| Prost-QA cohort (133) | 63.5 (27.8)            | 51.5 (30.0)              | −12.0 (−15.4 to −8.5)    | No                                      |

CI, confidence interval; EPIC, Expanded Prostate Cancer Index Composite; NHT, non-neoadjuvant hormonal therapy; SD, standard deviation.
<sup>a</sup> Scores range from 0-100, and higher scores indicate better patient reported quality of life.
<sup>b</sup> Mean difference >0.5 SD from baseline value.

Acknowledgments

This work was supported through the Congressionally Directed Medical Research Program under Award No. W81XWH-08-2-0174. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

References

1. Zelefsky MJ, Faks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. *Int J Radiat Oncol Biol Phys*. 2002;53:1111-1116.
2. Michalski JM, Yan Y, Watkins-Bruner D, et al. Preliminary toxicity analysis of 3DCRT versus IMRT on the high dose arm of the RTOG 126 prostate cancer trial. *Int J Radiat Oncol Biol Phys*. 2013;87:932-938.
3. De Meerleer G, Vakaet L, Meersschout S, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. *Int J Radiat Oncol Biol Phys*. 2004;60:777-787.
4. Maund IF, Benson RJ, Fairfoul J, Cook J, Huddart R, Poynter A. Image-guided radiotherapy of the prostate using daily CBCT: The feasibility and likely benefit of implementing a margin reduction. *Br J Radiol*. 2014;87:20140549.
5. Chandra A, Dong L, Huang E, et al. Experience of ultrasound-based daily prostate localization. *Int J Radiat Oncol Biol Phys*. 2003;56:436-447.
6. Little DJ, Dong L, Levy LB, Chandra A, Kuban DA. Use of portal images and BAT ultrasonography to measure setup error and organ motion for prostate IMRT: Implications for treatment margins. *Int J Radiat Oncol Biol Phys*. 2003;56:1218-1224.
1. Smitsmans MH, de Bois J, Sonke JJ, et al. Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy. *Int J Radiat Oncol Biol Phys*. 2005;63:975-984.

2. Bell LJ, Eade T, Kneebone A, et al. Initial experience with intrafraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. *J Med Radiat Sci*. 2017;64:25-34.

3. Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image-guided radiotherapy with non-IGRT for the treatment of clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012;84:125-129.

4. Foster RD, Pistemaa DA, Soldberg TD. A comparison of radiographic techniques and electromagnetic transponders for localization of the prostate. *Radiat Oncol*. 2012;7:101.

5. Willoughby TR, Kupelian PA, Pouliot J, et al. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2006;65:528-534.

6. Loveck DM, Messineo AP, Cox BW, Kollmeier MA, Zelefsky MJ. Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy. *Int J Radiat Oncol Biol Phys*. 2015;91:588-594.

7. Langen KM, Willoughby TR, Meeks SL, et al. Observations on real-time prostate gland motion using electromagnetic tracking. *Int J Radiat Oncol Biol Phys*. 2008;71:1084-1090.

8. Olsen JR, Noel CE, Baker K, et al. Practical method of adaptive radiotherapy for prostate cancer using real-time electromagnetic tracking. *Int J Radiat Oncol Biol Phys*. 2012;82:1903-1911.

9. Mayyas E, Chetty IJ, Chetvertkov M, et al. Evaluation of multiple image-based modalities for image-guided radiation therapy (IGRT) of prostate carcinoma: A prospective study. *Med Phys*. 2013;40:041707.

10. Tanyi JA, He T, Summers PA, et al. Assessment of planning target volume margins for intensity-modulated radiotherapy of the prostate gland: Role of daily inter- and intrafraction motion. *Int J Radiat Oncol Biol Phys*. 2010;78:1579-1585.

11. Wilbert J, Baier K, Hermann C, et al. Accuracy of real-time couch tracking during 3-dimensional conformal radiation therapy, intensity modulated radiation therapy, and volumetric modulated arc therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2013;85:237-242.

12. Franz AM, Schmitt D, Seitel A, et al. Standardized accuracy assessment of the calypso wireless transponder tracking system. *Phys Med Biol*. 2014;59:6797-6810.

13. Lin Y, Liu T, Yang X, Wang Y, Khan MK. Respiratory-induced prostate motion using wavelet decomposition of the real-time electromagnetic tracking signal. *Int J Radiat Oncol Biol Phys*. 2013;87:370-374.

14. Shah AP, Kupelian PA, Willoughby TR. An evaluation of intrafraction motion of the prostate in the prone and supine positions using electromagnetic tracking. *Radiother Oncol*. 2011;99:37-43.

15. Lee NY, Lu JJ, eds. *Target Volume Delineation and Field Setup*. Berlin Heidelberg, Germany: Springer-Verlag; 2013.

16. Donovan JL, Handy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *N Engl J Med*. 2016;375:1425-1437.

17. Shelton J, Rossi PJ, Chen H, Liu Y, Master VA, Jani AB. Observations on prostate intrafraction motion and the effect of reduced treatment time using volumetric modulated arc therapy. *Pract Radiat Oncol*. 2011;1:243-250.

18. Hall WA, Fox TH, Jiang X, et al. Treatment efficiency of volumetric modulated arc therapy in comparison with intensity-modulated radiotherapy in the treatment of prostate cancer. *J Am Coll Radiol*. 2013;10:126-134.

19. Wei J, Dunn R, Litwin M, Sandler H, Sanda M. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. *Urology*. 2000;56:999-905, 2000.

20. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. *N Engl J Med*. 2008;358:1250-1261.

21. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2008;70:1124-1129.

22. Fioreno C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy. *Pelvis Radiother Oncol*. 2009;93:153-167.

23. Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. *J Clin Oncol*. 2017;35:1884-1890.

24. Deaneley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, Phase 3 CHHiP trial. *Lancet Oncol*. 2016;17:1047-1060.

25. Sandler HM, Liu PY, Dunn RL, et al. Reduction in patient reported acute morbidity in prostate cancer patients treated with 81Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: Assessing the impact of margin reduction study. *Urology*. 2010;75:10048.

26. Sun K, Kathpal M, Tinnell B, et al. Radiation therapy for prostate cancer with reduced PTV. Poster session presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium. February 26-28, 2005; Orlando, FL.